NeOnc Technologies Holdings Inc(NTHI) - 2025 Q4 - Annual Report

Product Development - NeOnc is developing two lead products: NEO100, which is in Phase IIa trials, and NEO212, which has received IND approval and is set to begin clinical trials in Q4 2023[22][26]. - The Phase IIa trial for NEO100 has expanded eligibility to include patients with recurrent Grade III IDH1/2 mutant astrocytomas, increasing the potential enrollment pool significantly[24]. - NEO212 has established a recommended Phase 2 dose of 610 mg, with preliminary observations suggesting anti-tumor activity in heavily pretreated patients[27]. - The ongoing Phase IIa trials aim to confirm dosing requirements and assess the drug's performance in a larger patient population[52]. - The company is also conducting a Phase I/II trial for oral NEO212, targeting various solid tumors with brain metastases[69]. - NEO212 has received FDA approval for oral administration in 2023, enabling Phase I/IIa clinical trials focusing on patients with intracranial malignancies[79]. Clinical Trial Results - In the Phase I trial of NEO100, 21% of patients showed radiographic responses, exceeding the historical response rates of <8% for recurrent high-grade gliomas[25]. - NEO100's Phase I trial demonstrated that 37% of patients were alive two years after treatment, compared to an average life expectancy of six months for recurrent glioblastoma patients[35]. - In a Phase I trial, 25% of patients with recurrent glioblastoma survived for at least 4 years, indicating preliminary signs of activity for NEO100[41][44]. - Among 12 patients in the Phase I trial, 55% survived more than one year, and 33% survived over two years[44]. - The Phase IIa study for NEO100 includes 25 patients with recurrent glioblastoma and aims to evaluate progression-free survival at six months[53][54]. - In a Phase I clinical trial, intranasal NEO100 demonstrated a progression-free survival (PFS-6) rate of 33% and an overall survival (OS-12) rate of 55% among 12 patients[100]. - The ongoing Phase 1/2a study of intranasal NEO100 has enrolled 25 patients, with 24% showing radiographic responses and 44% achieving progression-free survival at six months[103]. Drug Delivery Methods - NEO100 is being investigated for its potential to bypass the blood-brain barrier (BBB) for drug delivery, with proof of concept observed in animal models but not yet in humans[40]. - NEO100's intranasal delivery method allows for convenient administration at home, avoiding invasive procedures[51]. - NEO100's intranasal delivery method allows for direct brain access, potentially avoiding the blood-brain barrier and reducing systemic side effects[86]. - The company is exploring three drug delivery pathways using NEO100, with intranasal delivery being the only one currently in clinical testing[83]. - Intra-arterial delivery of NEO100 demonstrated the ability to open the blood-brain barrier, allowing therapeutic agents to enter the brain in mouse models[119]. Market Potential - The global CNS treatment market is projected to grow at a CAGR of 8.6% to reach $267.6 billion by 2034, while the brain tumor drug market is expected to grow at a CAGR of 9.8% to reach $4.6 billion by 2032[91]. - The GBM drug market is anticipated to grow at a CAGR of 9.8% to $4.4 billion by 2023, driven by an increasing geriatric population and rising incidence rates[92]. - The average life expectancy for patients with newly-diagnosed glioblastoma is currently only 15 months, highlighting the urgent need for effective treatments like NEO212[137]. Regulatory and Compliance - The company has no commercial products or sales infrastructure, and must conduct clinical trials to obtain regulatory approvals[28]. - The FDA regulates the approval process for new drug products, requiring substantial time and financial resources for compliance with testing and manufacturing standards[183][184]. - The company must submit a new drug application (NDA) to the FDA, which includes evidence of safety and efficacy from clinical trials, before marketing any new drug product[189]. - The FDA requires extensive monitoring and auditing of clinical activities, with annual progress reports detailing clinical trial results submitted to the FDA[192]. - Manufacturers must comply with cGMP regulations, including quality control and assurance, to maintain product safety and efficacy[216]. Intellectual Property - The company holds exclusive rights to 28 issued patents and 14 pending patent applications in the U.S., with a total of 65 issued patents and 28 pending applications internationally[147]. - The company has filed multiple patent applications for its product candidates, including NEO100 and NEO212, with expiration dates ranging from 2031 to 2038[150]. - The company is responsible for all reasonable patent expenses incurred by USC for filing, prosecution, and maintenance of the licensed patents[157]. - The patent prosecution process is complex and may require narrowing claims, which could limit the scope of patent protection[153]. Financial Obligations - The company has a litigation settlement payable of $4 million to OEP, which is recorded in the consolidated balance sheets as of December 31, 2025 and 2024[169]. - The company has settled a dispute with Fox Infused for $600,000, payable within 5 business days of the closing date of the initial public offering, with accumulated interest of 10% per annum for any default[179]. - The company must pay USC $230,000 by March 31, 2024, to satisfy prior unpaid sublicense issue royalties and annual maintenance royalties due for sublicensees[166]. Competitive Landscape - The competitive landscape for CNS treatments includes established players like Pfizer, Roche, and Novartis, as well as emerging therapies such as gene therapies and biologics[138][141]. - The company is investigating additional proprietary chemotherapy agents that have shown positive effects in laboratory tests for various cancers, including NEO212 for brain cancer[149]. Future Strategies - Future growth strategies include potential commercial launch of NEO100 following FDA approval and exploration of pediatric indications for NEO100[149]. - The company aims to change the cancer therapeutic landscape by developing novel drug delivery methods combined with new drug candidates[94].